▸ THE ONE-LINER

Seventy-three insider sells this week. One buy.

Vertex Pharmaceuticals entered into a material definitive agreement, the details of which are disclosed under Item 1.01 alongside a Regulation FD disclosure. The filing's multi-item structure suggests a meaningful business development event, potentially a licensing deal, collaboration, or acquisition. With VRTX sitting near its 52-week high of $530, any strategic agreement that expands its pipeline beyond cystic fibrosis could justify the elevated valuation.

Analog Devices closed a new credit facility, adding a direct financial obligation to its balance sheet at a time when the stock sits near the midpoint of its 52-week range. The move suggests management is positioning for flexibility, whether for M&A, capital returns, or refinancing existing debt. ADI already carries a meaningful debt load from its Maxim acquisition, so investors will want to watch the terms and size closely. More covenant or maturity detail will likely emerge in the full exhibit filing.

S&P Global closed its acquisition of a majority stake in Visible Alpha, a consensus data and analytics platform used widely by institutional investors. The deal adds granular sell-side estimate data to SPGI's existing Market Intelligence segment, filling a gap that competitors like Bloomberg and FactSet have been quietly exploiting. With the stock sitting near the lower half of its 52-week range, investors will be watching whether bolt-on deals like this can reignite the growth narrative.

SPREAD THE FILE

KNOW SOMEONE WHO
TRACKS THE INSIDERS?